



**SENATE BILL 309
GENERAL LAW COMMITTEE
PUBLIC HEARING: 3/3/16**

**SENATE BILL 309 -- *AN ACT ESTABLISHING A TASK FORCE TO STUDY
VALUE-BASED PRICING OF PRESCRIPTION DRUGS***

The Connecticut Center for Patient Safety supports Senate Bill 309 and we applaud the General Law Committee for addressing the very important issue of value-based pricing.

Xconomy.com reports that Germany and the United Kingdom have already seen successes with a system of value-based pricing, which requires pharma companies to provide details of how they arrive at fair prices for their innovations, while also more clearly demonstrating the value to patients.

In Germany, for example, the new rules require pharma companies to negotiate prices for new drugs with health insurers, severely limiting pharma companies' previous freedom to set prices. If the new treatment has no therapeutic benefit, then reimbursement by the insurance company for such medicine will be set at a level no greater than the comparable medicines already on the market.

The Connecticut Center for Patient Safety is looking forward to participating in the Task Force research and deliberations.

Please Support Senate Bill 309.

Contacts: Jean Rexford, Lisa Freeman, Bob Shea